United States Metabolic Disorders Market Outlook to 2036 – Diabetes Assays and Cholesterol Tests

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: May 30, 2026 Report Code: GDME5577CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “United States Metabolic Disorders Market Outlook to 2036” is a comprehensive databook report, covering key market data on the United States Metabolic Disorders market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Diabetes Assays, Cholesterol Tests

The United States Metabolic Disorders Market report provides key information and data on –
– Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2024 to 2036.
– 2025 company share data for Metabolic Disorders Market.
– Global corporate-level profiles of key companies operating within the United States Metabolic Disorders Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States Metabolic Disorders is segmented as follows:

– Diabetes Assays

– Cholesterol Tests

Reasons to Buy

The United States Metabolic Disorders Market report helps you to develop:

– Business strategies by identifying the key market segments poised for strong growth in the future.

– Market-entry and market expansion strategies.

– Design competition strategies by identifying who-stands-where in the market.

– Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

Abbott Laboratories
Siemens Healthineers AG
Roche Diagnostics International Ltd
Ortho Clinical Diagnostics Holdings Ltd (Inactive)
Beckman Coulter Inc

Table of Contents_x000D_

List of Tables_x000D_

List of Figures_x000D_

1 Introduction_x000D_

1.1 What Is This Report About?_x000D_

1.2 Metabolic Disorders Market Segmentation_x000D_

1.3 Definitions of Markets Covered in the Report_x000D_

2 Metabolic Disorders Market, United States_x000D_

2.1 Metabolic Disorders Market, United States, Revenue ($m), 2024-2036_x000D_

2.1.1 Cholesterol Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_

2.1.2 Diabetes Assays Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_

2.2 Metabolic Disorders Market, United States, Volume (Units), 2024-2036_x000D_

2.2.1 Cholesterol Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_

2.2.2 Diabetes Assays Market, United States, Volume (Units), by Segment, 2024-2036_x000D_

2.3 Metabolic Disorders Market, United States, Average Price ($), 2024-2036_x000D_

2.4 Metabolic Disorders Market, United States, Company Share by Revenue ($m), 2025_x000D_

3 Metabolic Disorders Market Pipeline Products_x000D_

3.1 Metabolic Disorders Market Pipeline Products_x000D_

3.2 Metabolic Disorders – Pipeline Products by Stage of Development_x000D_

3.3 Metabolic Disorders – Pipeline Products by Segment_x000D_

3.4 Metabolic Disorders – Pipeline Products by Territory_x000D_

3.5 Metabolic Disorders – Pipeline Products by Regulatory Path_x000D_

3.6 Metabolic Disorders – Pipeline Products by Estimated Approval Date_x000D_

4 Overview of Key Companies in United States, Metabolic Disorders Market_x000D_

4.1 Abbott Laboratories_x000D_

4.1.1 Company Overview_x000D_

4.2 Siemens Healthineers AG_x000D_

4.2.1 Company Overview_x000D_

4.3 Roche Diagnostics International Ltd_x000D_

4.3.1 Company Overview_x000D_

4.4 Ortho Clinical Diagnostics Holdings Ltd (Inactive)_x000D_

4.4.1 Company Overview_x000D_

4.5 Beckman Coulter Inc_x000D_

4.5.1 Company Overview_x000D_

5 Recent Developments_x000D_

5.1 Corporate Communications_x000D_

5.1.1 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors_x000D_

5.1.2 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_

5.1.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth_x000D_

5.1.4 Nov 01, 2025: Dale Medical Products, Inc. Introduces IV Line Manager_x000D_

5.1.5 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder_x000D_

5.1.6 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_

5.2 Other Significant Developments_x000D_

5.2.1 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months_x000D_

5.2.2 Nov 13, 2025: Cleveland Clinic Pitch Competition Awards $100,000 Grant to AutoCMR Inventors_x000D_

5.2.3 Nov 05, 2025: IU Fuels Indiana’s Next Wave of Industry Growth_x000D_

5.2.4 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_

5.3 Product News_x000D_

5.3.1 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics_x000D_

5.3.2 Nov 28, 2025: Mike Bako and RENPHO Showcase Health Technology on YourUpdateTV_x000D_

5.3.3 Nov 17, 2025: Inmedix CloudHRV System Surpasses 1000 Procedures in Its First 5 Months_x000D_

5.3.4 Oct 28, 2025: EMulate Therapeutics Launches Community Investment Round on Wefunder_x000D_

5.3.5 Oct 20, 2025: SRI Multi-Party Team Selected as Awardee by ARPA-H to Develop At-Home Screening for 30 Types of Cancers_x000D_

5.3.6 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies_x000D_

5.3.7 Jun 23, 2025: New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease_x000D_

5.4 Research And Development_x000D_

5.4.1 Oct 10, 2025: An International Project Employs 'Resurrected' Ancestral Enzymes for Cancer Prevention and Neurobiology Studies_x000D_

5.5 Strategy And Business Planning_x000D_

5.5.1 Apr 14, 2026: Vida Health and OURA to Deliver Continuous, Personalized Metabolic Care_x000D_

5.5.2 Mar 11, 2026: PatentVest Announces Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics_x000D_

5.5.3 Nov 11, 2025: Expanse Medical Expands to Providence, Rhode Island_x000D_

5.5.4 Nov 10, 2025: Synthego Introduces High-Performance Molecular Reagents for Diagnostics_x000D_

5.5.5 Nov 06, 2025: TEDCO Signs Agreement for Up to $50 Million Investment with TAIIDA and SFIC Group_x000D_

5.5.6 Nov 05, 2025: JLL Partners Announces Combination of Vascular Technology Incorporated and Parks Medical Electronics_x000D_

5.5.7 Oct 29, 2025: EazeBio And UC Santa Cruz Form Strategic Partnership For Instrument-Free Diagnostics_x000D_

6 Appendix_x000D_

6.1 Research Methodology_x000D_

6.1.1 Coverage_x000D_

6.1.2 Secondary Research_x000D_

6.1.3 Primary Research_x000D_

6.1.4 Market Modeling and Forecasting_x000D_

6.1.5 Company Share Analysis_x000D_

6.1.6 Benchmarking_x000D_

6.2 GlobalData Consulting_x000D_

6.3 Contact Us_x000D_

6.4 Disclaimer

Table

Table 1: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036

Table 2: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036

Table 3: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036

Table 4: Metabolic Disorders Market, United States, Volume (Units), 2024-2036

Table 5: Cholesterol Tests Market, United States, Volume (Units), 2024-2036

Table 6: Diabetes Assays Market, United States, Volume (Units), 2024-2036

Table 7: Metabolic Disorders Market, United States, Average Price ($), 2024-2036

Table 8: Metabolic Disorders Market, United States, Company Share by Revenue ($m), USD Constant, 2025

Table 9: Metabolic Disorders Market Pipeline Products

Table 10: Metabolic Disorders – Pipeline Products by Stage of Development

Table 11: Metabolic Disorders Companies – Pipeline Products by Stage of Development

Table 12: Metabolic Disorders – Pipeline Products by Segment

Table 13: Metabolic Disorders – Pipeline Products by Territory

Table 14: Metabolic Disorders – Pipeline Products by Regulatory Path

Table 15: Metabolic Disorders – Pipeline Products by Estimated Approval Date

Table 16: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

Figures

Figure 1: Metabolic Disorders Market, United States, Revenue ($m), USD Constant, 2024-2036

Figure 2: Cholesterol Tests Market, United States, Revenue ($m), USD Constant, 2024-2036

Figure 3: Diabetes Assays Market, United States, Revenue ($m), USD Constant, 2024-2036

Figure 4: Metabolic Disorders Market, United States, Volume (Units), 2024-2036

Figure 5: Cholesterol Tests Market, United States, Volume (Units), 2024-2036

Figure 6: Diabetes Assays Market, United States, Volume (Units), 2024-2036

Figure 7: Metabolic Disorders Market, United States, Company Share (%), 2025

Figure 8: Metabolic Disorders – Pipeline Products by Stage of Development

Figure 9: Metabolic Disorders – Pipeline Products by Segment

Figure 10: Metabolic Disorders – Pipeline Products by Territory

Figure 11: Metabolic Disorders – Pipeline Products by Regulatory Path

Figure 12: Metabolic Disorders – Pipeline Products by Estimated Approval Date

United States Metabolic Disorders Market Outlook to 2036 – Diabetes Assays and Cholesterol Tests standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United States Metabolic Disorders Market Outlook to 2036 – Diabetes Assays and Cholesterol Tests in real time.

Access a live United States Metabolic Disorders Market Outlook to 2036 – Diabetes Assays and Cholesterol Tests dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

United States Metabolic Disorders Market Outlook to 2036 – Diabetes Assays and Cholesterol Tests

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports